Shareholders Throw Their Weight Behind BioNTech’s Costly Cancer Makeover as the Stock Stalls

BioNTech shareholders gave 92% approval for oncology transformation at AGM, backing billions in R&D spending while stock dips 8% monthly. €16.8B war chest funds the pivot.

BioNTech’s virtual annual general meeting on Friday delivered exactly what management wanted: a near-unanimous vote of confidence in a transformation that is burning billions and has yet to produce a commercial oncology product. With 92% of the represented capital backing every resolution, investors signalled they are willing to ride out the pain while the company pivots from pandemic star to cancer specialist.

The endorsement came despite a share price that has been drifting lower. BioNTech stock ended the session at €76.95, down 2% on the day and roughly 8% weaker over the past month. The gap to its 50-day moving average of €81.70 underscores a bearish technical setup that stands in sharp contrast to the enthusiasm inside the virtual shareholder room.

A Financial Cushion That Buys Time

The company’s war chest remains its most powerful weapon. At the end of the first quarter, liquid assets stood at €16.8 billion — enough to fund years of heavy R&D spending without external pressure. For 2026, management forecasts revenue of €2.0–2.3 billion, while research and development costs are expected to reach €2.2–2.5 billion, meaning the drug development bill will exceed sales again this year. Selling and administrative expenses are pegged at €700–800 million.

To soften the drain, BioNTech is streamlining its manufacturing footprint, consolidating production sites in a move expected to generate annual savings of roughly €500 million once fully implemented. Shareholders also authorised a multi-billion euro share buyback programme for the coming twelve months, a signal that management believes the stock is undervalued even as the market remains sceptical.

Board Overhaul Reflects New Priorities

The AGM expanded the supervisory board from six to eight members, adding two executives with deep oncology credentials. Prof. Iris Löw-Friedrich brings experience in clinical development, while Susanne Schaffert contributes expertise in oncology commercialisation. Their appointments align with a pipeline that now encompasses more than 20 active late-stage studies and 17 clinical programmes spanning a range of solid and haematological tumours. The company has already collected data from over 4,000 patients in its clinical database.

Helmut Jeggle was re-elected as chairman of the supervisory board, alongside continuing mandates for Prof. Anja Morawietz and Prof. Rudolf Staudigl. On the legal side, shareholders approved a new authorised capital resolution — dubbed “Authorised Capital 2026” — that can cover up to half of the current share capital, replacing the previous year’s expiring authority. They also ratified a domination and profit transfer agreement involving BioNTech Discovery GmbH, a structural move that allows the parent to offset subsidiary profits against group losses for tax purposes. The arrangement may seem technical, but it eases the financial burden of a research-heavy group structure.

The Pipeline Clock Is Ticking

Chief executive Ugur Sahin used the meeting to reiterate the ambition: ten oncology approvals by 2030. The near-term catalyst rests on a single molecule. Pumitamig, a bispecific immune modulator that Sahin described as the company’s flagship programme, is set for a public test at the end of May. BioNTech will present Phase 2 data from a lung cancer study at the American Society of Clinical Oncology (ASCO) annual meeting, where pumitamig is being tested head-to-head against pembrolizumab.

A positive readout would provide the first major external validation of the oncology pivot. A disappointment would throw the entire strategy into question.

Analyst Divergence Reflects Binary Bet

The uncertainty is baked into the stock’s valuation. Among 19 analysts covering BioNTech, 15 rate it a “Strong Buy” and four stay at “Hold”, but price targets range from $94 to $171 — a spread that highlights how dependent the share price is on upcoming clinical milestones. H.C. Wainwright, for instance, maintains a buy rating and a $130 target, citing progress with late-stage candidates such as pumitamig. Berenberg trimmed its target on 12 May but still described the stock as deeply undervalued.

For now, the market is waiting. The ASCO presentation later this month will deliver the first external judgment on whether BioNTech’s high-stakes bet on cancer is producing results worth betting on — or simply burning cash.